ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0567

Gain-of-Function Mutations in Lyn Kinase Cause a Novel Autoinflammatory Disease with Small Vessel Vasculitis and Liver Fibrosis

Adriana Almeida de Jesus1, Guibin Chen2, Dan Yang2, Tomas Brdicka3, Natasha Ruth4, David Bennin5, Dita Cebecauerova6, Hana Malcova7, Helen Freeman8, Neil Martin9, Karel Svojgr6, Murray Passo4, Farzana Bhuyan10, Sara Alehashemi11, Andre Rastegar12, Kat Uss12, Lela Kardova12, Iris Duric3, Ebun Omoyinmi13, Petra Peldova6, Chyi-Chia Richard Lee14, David Kleiner14, Colleen Hadigan15, Stephen Hewitt14, Stefania Pittaluga14, Carmelo Carmona-Rivera16, Katherine R. Calvo15, Nirali Shah14, Miroslava Balascakova6, Danielle Fink17, Radana Kotalova6, Zuzana Parackova6, Lucie Peterkova6, Daniela Kuzilkova6, Vit Campr6, Lucie Sramkova6, Stephen Brooks16, Eric Meffre18, Rebecca Harper2, Hyesun Kuehn15, Mariana Kaplan16, Paul Brogan19, Sergio Rosenzweig15, Zuoming Deng16, Anna Huttenlocher5, Susan Moir12, Douglas Kuhns17, Manfred Boehm2, Karolina Skvarova Kramarzova20 and Raphaela Goldbach-Mansky21, 1NIAID, NIH, Silver Spring, MD, 2National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 3Laboratory of Leukocyte Signaling, Institute of Molecular Genetics of the Academy of Sciences of Czech Republic (ASCR), Prague, Czech Republic, 4Medical University of South Carolina, Charleston, SC, 5Departments of Pediatrics and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, 6Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic, 7Second Faculty of Medicine, Charles University/University Hospital Motol, Praha, Czech Republic, 8Raigmore Hospital, Inverness, Scotland, United Kingdom, 9Royal Hospital for Children, Glasgow, Scotland, United Kingdom, 10National Institutes of Health, Bethesda, MD, 11NIH/NIAID/TADS, Clarksville, MD, 12National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 13Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 14National Cancer Institute, National Institutes of Health, Bethesda, MD, 15Clinical Center, National Institutes of Health, Bethesda, MD, 16National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 17National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, 18Yale University, New Haven, CT, 19UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 20Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, 21NIH/NIAID, Potomac, MD

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, genetics, neutrophils, skin, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Pediatric Rheumatology – Basic Science

Session Type: Abstract Session

Session Time: 8:00AM-9:00AM

Background/Purpose: Lyn kinase is a member of the Src family of tyrosine kinases that regulates innate and adaptive immune responses. Lyn C-terminal tail tyrosine residue, p.Y508, inactivates wildtype Lyn kinase upon phosphorylation. We describe 3 unrelated patients with de novo LYN mutations affecting p.Y508, whose disease sheds light on the pathogenesis of neutrophilic small vessel vasculitis.

Methods: All patients (Pts) were enrolled into an IRB-approved natural history protocol (NCT02974595). The effects of the LYN mutations were investigated in Pts’ and healthy control (HC) blood cells and serum, in transfection and immunological studies and in induced pluripotent stem cells (iPS cells)-derived endothelial cells (iECs).

Results: The three Pts presented with perinatal purpuric rash and systemic inflammation, hepatosplenomegaly, periorbital erythema, abdominal and testicular pain. Pts 1 and 3 had early onset liver fibrosis. Transiently elevated autoantibodies (ANA, anti-Sm, anti-SSA) were present in Pt 1. All patients had a skin biopsy showing neutrophilic small vessel vasculitis. The 3 Pts were found to have de novo mutations in LYN: p.Y508* in Pt 1, p.Y508F in Pt 2 and p.Q507* in Pt 3 and responded partially (Pts 1 and 3) or fully (Pt 2) to the TNF inhibitor etanercept. Combination therapy with the Src kinase inhibitor, dasatinib, led to resolution of liver fibrosis in Pt 1. Transfection of wildtype and mutant Lyn into HEK293FT cells showed constitutive phosphorylation of the activating tyrosine, p.Y397, and absent phosphorylation of the inhibitory tyrosine, p.Y508. Skin biopsies showed a dense neutrophilic infiltrate with small vessel wall destruction and neutrophil extracellular traps (NETs) formation; ICAM-1 was upregulated and focally colocalized with the EC marker CD31. All Pts showed elevated pro-inflammatory cytokines, and/or markers of neutrophil (L-selectin) and EC activation (ICAM-1, E-selectin) in serum. Monocyte-derived macrophages released increased levels of TNF-a, IL-6, CXCL10 and sICAM-1 upon LPS stimulation. Neutrophils from Pt 1 showed signs of constitutive activation, including high surface expression of b2-integrins. Expression of ICAM-1 in areas of adherent neutrophils were increased in Pt 1 iEC/HC neutrophil co-cultures compared to isogenic and HC iEC. Neutrophil adhesion and ICAM-1 clusters were blocked with dasatinib and less with the TNF inhibitor. Transendothelial migration of HC neutrophils through Pt 1 iECs was increased compared to isogenic or HC iECs and reduced by treatment with dasatinib or TNF inhibitor.

Conclusion: We describe a novel autoinflammatory disease which we called Lyn associated vasculopathy and liver fibrosis (LAVLI). De novo activating LYN mutations link Lyn kinase to regulating dermal vascular permeability, restricting inflammatory signals in immune cells, and promoting hepatic fibrosis. Functional data support a stepwise approach to treatment of reserving dasatinib for patients with liver fibrosis and insufficient responses to TNF inhibition. This study identifies Lyn kinase as potential treatment target in neutrophilic small vessel vasculitis and early liver fibrosis.

This study was supported in part by the IRP of NIAID, NIH.


Disclosures: A. Almeida de Jesus, None; G. Chen, None; D. Yang, None; T. Brdicka, None; N. Ruth, None; D. Bennin, None; D. Cebecauerova, None; H. Malcova, None; H. Freeman, None; N. Martin, None; K. Svojgr, None; M. Passo, None; F. Bhuyan, None; S. Alehashemi, None; A. Rastegar, None; K. Uss, None; L. Kardova, None; I. Duric, None; E. Omoyinmi, None; P. Peldova, None; C. Lee, None; D. Kleiner, None; C. Hadigan, None; S. Hewitt, None; S. Pittaluga, None; C. Carmona-Rivera, None; K. Calvo, None; N. Shah, None; M. Balascakova, None; D. Fink, None; R. Kotalova, None; Z. Parackova, None; L. Peterkova, None; D. Kuzilkova, None; V. Campr, None; L. Sramkova, None; S. Brooks, None; E. Meffre, None; R. Harper, None; H. Kuehn, None; M. Kaplan, None; P. Brogan, None; S. Rosenzweig, None; Z. Deng, None; A. Huttenlocher, None; S. Moir, None; D. Kuhns, None; M. Boehm, None; K. Skvarova Kramarzova, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Almeida de Jesus A, Chen G, Yang D, Brdicka T, Ruth N, Bennin D, Cebecauerova D, Malcova H, Freeman H, Martin N, Svojgr K, Passo M, Bhuyan F, Alehashemi S, Rastegar A, Uss K, Kardova L, Duric I, Omoyinmi E, Peldova P, Lee C, Kleiner D, Hadigan C, Hewitt S, Pittaluga S, Carmona-Rivera C, Calvo K, Shah N, Balascakova M, Fink D, Kotalova R, Parackova Z, Peterkova L, Kuzilkova D, Campr V, Sramkova L, Brooks S, Meffre E, Harper R, Kuehn H, Kaplan M, Brogan P, Rosenzweig S, Deng Z, Huttenlocher A, Moir S, Kuhns D, Boehm M, Skvarova Kramarzova K, Goldbach-Mansky R. Gain-of-Function Mutations in Lyn Kinase Cause a Novel Autoinflammatory Disease with Small Vessel Vasculitis and Liver Fibrosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/gain-of-function-mutations-in-lyn-kinase-cause-a-novel-autoinflammatory-disease-with-small-vessel-vasculitis-and-liver-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gain-of-function-mutations-in-lyn-kinase-cause-a-novel-autoinflammatory-disease-with-small-vessel-vasculitis-and-liver-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology